Evidence map›Paper›PMID 25171599›Full record

ArticleEndocrinology2014

Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs.

Laura A Maile, Walker H Busby, Katherine A Gollahon, William Flowers, Nikol Garbacik, Stefani Garbacik, Kara Stewart, Timothy Nichols, Dwight Bellinger, Amit Patel and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The Functions of SARS-CoV-2 Receptors in Diabetes-Related Severe COVID-19.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. suPAR: An Inflammatory Mediator for Kidneys.Kidney diseases (Basel, Switzerland) · 2022
    Review
  10. Observational
  11. Article
  12. Observational
  13. PodocyteFrontiers in pharmacology · 2021
    Article
  14. Review
  15. Long-term case study of a Wuzhishan miniature pig with diabetes.Animal models and experimental medicine · 2020
    Article
  16. Soluble Urokinase Receptor and Acute Kidney Injury.The New England journal of medicine · 2020
    Article
  17. Animal Models of Diabetes-Associated Renal Injury.Journal of diabetes research · 2020
    Review
  18. Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  19. Emerging strategies to disrupt the central TGF-β axis in kidney fibrosis.Translational research : the journal of laboratory and clinical medicine · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Laura A MaileDepartment of Medicine (L.A.M., W.H.B., K.A.G., T.N., D.B., A.P., P.D., M.M., D.C.), University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599; and Department of Animal Science (W.F., N.G., S.G., K.S.), North Carolina State University, Raleigh, North Carolina 27695.
Walker H Busby
Katherine A Gollahon
William Flowers
Nikol Garbacik
Stefani Garbacik
Kara Stewart
Timothy Nichols
Dwight Bellinger
Amit Patel
Paul Dunbar
Matt Medlin
David Clemmons
University of North Carolina at Chapel Hill · USNorth Carolina State University · US

Funding

Development of a Novel Method for Inhibiting Atherosclerosis in DiabetesR42HL084857 · NHLBI · VASCULAR PHARMACEUTICALS · PI CLEMMONS, DAVID R · 2009 to 2010
$1.2M
Development of a Novel Method for Inhibiting Atherosclerosis in DiabetesR41HL084857 · NHLBI · VASCULAR PHARMACEUTICALS · PI CLEMMONS, DAVID ROBERT · 2006 to 2006
$210k
NHLBI NIH HHS HL084857NHLBI NIH HHS R41 HL084857NHLBI NIH HHS R42 HL084857
6 · The paper itself

Abstract

Hyperglycemia stimulates secretion of αVβ3 ligands from vascular cells, including endothelial cells, resulting in activation of the αVβ3 integrin. This study determined whether blocking ligand occupancy of αVβ3 would inhibit the development of diabetic nephropathy. Ten diabetic pigs received an F(ab)2 fragment of an antibody directed against the extracellular domain of the β3-subunit, and 10 received a control IgG F(ab)2 for 18 weeks. Nondiabetic pigs excreted 115 ± 50 μg of protein/mg creatinine compared with control F(ab)2-treated diabetic animals (218 ± 57 μg/mg), whereas diabetic animals treated with the anti-β3 F(ab)2 excreted 119 ± 55 μg/mg (P < .05). Mesangial volume/glomerular volume increased to 21 ± 2.4% in control-treated diabetic animals compared with 14 ± 2.8% (P < .01) in animals treated with active antibody. Diabetic animals treated with control F(ab)2 had significantly less glomerular podocin staining compared with nondiabetic animals, and this decrease was attenuated by treatment with anti-β3 F(ab)2. Glomerular basement membrane thickness was increased in the control, F(ab)2-treated diabetic animals (212 ± 14 nm) compared with nondiabetic animals (170 ± 8.8 nm), but it was unchanged (159.9 ± 16.4 nm) in animals receiving anti-β3 F(ab)2. Podocyte foot process width was greater in control, F(ab)2-treated, animals (502 ± 34 nm) compared with animals treated with the anti-β3 F(ab)2 (357 ± 47 nm, P < .05). Renal β3 tyrosine phosphorylation decreased from 13 934 ± 6437 to 6730 ± 1524 (P < .01) scanning units in the anti-β3-treated group. We conclude that administration of an antibody that inhibits activation of the β3-subunit of αVβ3 that is induced by hyperglycemia attenuates proteinuria and early histologic changes of diabetic nephropathy, suggesting that it may have utility in preventing the progression of this disease complication.

Indexed as

AnimalsAntibodies, MonoclonalDiabetic NephropathiesGlomerular Basement MembraneIntegrin alphaVbeta3MaleMice, Inbred BALB CPodocytesProteinuriaSwineAntibodies, MonoclonalIntegrin alphaVbeta3

Identifiers

PMID25171599
PMCPMC4239428
OpenAlexW1963849856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.